Search Grant Opportunities

NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3 Clinical Trial Optional)

ID: PAR-21-092 • Type: Posted
Opportunity Assistant

Hello! Please let me know your questions about this opportunity. I will answer based on the available opportunity documents.

Sign in to upload a capability statement or catalogue for your company

Some suggestions:
Please summarize the work to be completed under this opportunity
Who is eligible to apply for this grant?
I'd like to anonymously submit a question to the procurement officer(s)
Loading

Description

The purpose of this award is to support outstanding basic and/or clinical researchers with the vision and expertise to translate research discoveries into medications for the treatment of Substance Use Disorders (SUDs) stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use. Eligible applicants must demonstrate the ability to develop molecules with the potential to treat SUDs and advance them in the drug development continuum. The ultimate goal of this FOA is to bring molecules closer to FDA approval.

Overview

Category of Funding
Education
Health
Funding Instruments
Cooperative Agreement
Grant Category
Discretionary
Cost Sharing / Matching Requirement
False
Source
On 12/21/20 the National Institutes of Health posted grant opportunity PAR-21-092 for NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3 Clinical Trial Optional) with funding of $2.0 million. The grant will be issued under grant program 93.279 Drug Abuse and Addiction Research Programs. It is expected that 2 total grants will be made.

Timing

Posted Date
Dec. 21, 2020, 12:00 a.m. EST
Closing Date
July 25, 2023, 12:00 a.m. EDT Past Due
Last Updated
Dec. 21, 2020, 11:52 a.m. EST
Version
1
Archive Date
Aug. 30, 2023

Eligibility

Eligible Applicants
Independent school districts
Public and State controlled institutions of higher education
Others (see text field entitled "Additional Information on Eligibility" for clarification)
County governments
For profit organizations other than small businesses
City or township governments
State governments
Public housing authorities/Indian housing authorities
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Small businesses
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Special district governments
Native American tribal organizations (other than Federally recognized tribal governments)
Native American tribal governments (Federally recognized)
Private institutions of higher education
Additional Info
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Award Sizing

Ceiling
$1,000,000
Floor
Not Listed
Estimated Program Funding
$2,000,000
Estimated Number of Grants
2

Contacts

Contact
National Institutes of Health
Contact Email
Email Description
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Contact Phone
(301) 402-2541

Documents

Posted documents for PAR-21-092

Grant Awards

Grants awarded through PAR-21-092

Incumbent or Similar Grants

Similar Active Opportunities

Open grant opportunities similar to PAR-21-092

Experts for NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3 Clinical Trial Optional)

Recommended subject matter experts available for hire